AstraZeneca: sharp rise in Q3 core EPS
(CercleFinance.com) - AstraZeneca announces that its sales reached £13.
56bn in Q3, up 18% y-o-y (+21% at constant exchange rates).
At the same time, the company reported core EPS of $2.08, up 20% (+27% at constant exchange rates).
The quality and impact of our scientific research was widely recognised this quarter, with data on AstraZeneca medicines presented in a record number of five presidential plenary sessions at the two major oncology conferences in September, management said.
It is also 'very encouraged' by the broad-based momentum seen across the business in 2024, and 'growth looks set to continue through to 2025, providing a solid foundation for achieving our 2030 ambition.
The laboratory announces that its full-year sales are now expected to rise by around 17% to 19% (vs. around 15% to 17% previously), while core EPS is expected to rise by around 17% to 19% (vs. 15% to 17% previously).
Finally, the laboratory confirms that it is taking the ongoing investigation in China 'very seriously', and confirms that if requested to do so, it will fully cooperate with the authorities.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
56bn in Q3, up 18% y-o-y (+21% at constant exchange rates).
At the same time, the company reported core EPS of $2.08, up 20% (+27% at constant exchange rates).
The quality and impact of our scientific research was widely recognised this quarter, with data on AstraZeneca medicines presented in a record number of five presidential plenary sessions at the two major oncology conferences in September, management said.
It is also 'very encouraged' by the broad-based momentum seen across the business in 2024, and 'growth looks set to continue through to 2025, providing a solid foundation for achieving our 2030 ambition.
The laboratory announces that its full-year sales are now expected to rise by around 17% to 19% (vs. around 15% to 17% previously), while core EPS is expected to rise by around 17% to 19% (vs. 15% to 17% previously).
Finally, the laboratory confirms that it is taking the ongoing investigation in China 'very seriously', and confirms that if requested to do so, it will fully cooperate with the authorities.
Copyright (c) 2024 CercleFinance.com. All rights reserved.